PreComb Therapeutics Logo
greybar
Linkedin   Twitter  


About       Team       Technology       News       Contact      





PreComb corporate news

Oct. 2018   
PreComb Therapeutics appoints Dr. Andrew Thomas as Strategic Advisor 
Wädenswil, October 18th, 2018
Andrew Thomas PDF






PreComb, the leader in 3D microtumor combinatorial drug discovery, is excited to announce the appointment of Dr. Andrew Thomas as a new member of the Strategic Advisory Board. Dr. Thomas brings a wealth of expertise from over 20 year of key positions in global Pharma companies and small molecule drug discovery and development.

Dr. Thomas has previously been Global Head of Medicinal Chemistry at Roche, being responsible for creating and developing an innovative portfolio of small molecule medicines for Neuroscience, Ophthalmology, Rare Diseases, Inflammation, Infectious Diseases, Immunology and Oncology. He is a founder and executive partner of IPSO group, Investment Director at Helvetica Capital and an active driver of the Swiss Entrepreneurs Foundation.
“We are proud to welcome Andrew in our Advisory Board” said Jens Kelm, CEO of PreComb. “His wealth of pharma experience in drug discovery and development and his entrepreneurial thinking will add tremendous value to our company and our mission to deliver novel combination therapies for difficult to treat cancers."


About PreComb Therapeutics

PreComb Therapeutics AG is a swiss-based biotechnology company focusing on the development of novel combination therapies, primarily for the use in oncology and immuno-oncology. PreComb is developing a phenotypical drug development platform using 3D microtumor cultures to enable high-throughput 3D combinatorial drug screening. The platform shall deliver more efficient cancer therapies to substantially improve long-term prognosis and quality-of-life for patients.

For more Information about PreComb Therapeutics, please visit https://www.precomb.com or follow us on LinkedIn.


Media contact

PreComb Therapeutics AG
Dr. Peter Steiner



 

Sept. 2018   
PreComb announces the formation of the Strategic Advisory Board
Wädenswil, September 21st, 2018
PDF Advisory Board



PreComb, the leader in micro-tumor based drug discovery, today announced the formation of its new advisory board, a strategic committee of trusted advisors.

"The search for experienced Advisory Board members to support the development of PreComb has been a thoughtful exercise" said Jens M. Kelm, CEO of PreComb Therapeutics. "We've been very fortunate to attract highly networked advisors with extensive practical experiences in Biotech industry, preclinical and clinical cancer research. We are looking forward to work with our advisors to quickly implement our ideas and leverage their expertise to develop novel anti-cancer combination therapies.

Appointments of the Strategic advisory board include:

Dominik Escher, PhD - Founding partner of Puros Bioventures and former founder and CEO of ESBATech AG

Prof. Heinz Zwierzina, MD - Head of the Early Clinical Trial Unit within the Department for Haematology and Oncology at the University Hospital, Innsbruck

Prof. Laura Suter-Dick, PhD - Professor for Molecular Toxicology at the University of Applied Sciences Northwestern Switzerland (FHNW)



About PreComb Therapeutics

PreComb Therapeutics AG is a swiss-based biotechnology company focusing on the development of novel combination therapies, primarily for the use in oncology and immuno-oncology. PreComb is developing a phenotypical drug development platform using 3D microtissue culture to enable high-throughput combinatorial drug screening. The platform shall deliver more efficient cancer therapies to substantially improve long-term prognosis and quality-of-life for patients.

For more Information about PreComb Therapeutics, please visit https://www.precomb.com or follow us on LinkedIn.


Media contact

PreComb Therapeutics AG
Dr. Peter Steiner





















Redpix
  Impressum/Disclaimer
© 2018 PreComb Therapeutics AG